The FDA says it will change how it looks at drugs for rare diseases. It announced the plan Wednesday, Oct. 14. The FDA calls it the Rare Disease Framework Initiative.
The FDA gave a reason. In a new report, it says only about 5 percent of known rare diseases have an approved treatment. The report says 30 million Americans, about one in ten, live with a rare disease.
By federal law, a disease is rare if it hits fewer than 200,000 people in the country. Many hit far fewer. The report says some have only a few hundred patients in the whole world.
That makes drug testing hard. The FDA says there are few patients to sign up for a study. The report says little is known about how many of these diseases change over time. The usual tests may not work for very small groups.
What will change? The FDA has not said yet. It wants advice and decisions that fit each disease. It lists six goals. They include clearer decisions. They include hearing from patients early and using outside experts. They include more training for FDA reviewers. They include a risk-based look at how drugs are made. They also include using cutting-edge science. The goal is to get treatments to patients sooner.
The FDA says this could mean new guidance, new rules and changes inside the agency. It says it will keep its safety standards.
Robert F. Kennedy Jr., the Health Secretary, said the FDA is "putting patients at the center." Kyle Diamantas, the acting FDA commissioner, said the agency wants a steady, predictable way to review these drugs.
The report uses the term "fit-for-purpose." That means the proof the FDA asks for should fit each disease. The FDA's Rare Disease Innovation Hub is leading the effort. Amy Comstock Rick runs the hub.
The public can weigh in. The FDA will hold a meeting on Oct. 28 at its White Oak campus in Maryland. A group called the Reagan-Udall Foundation will run it. The FDA says more chances to speak up will follow. They include roundtables and requests for information.
There is a Texas link. El Tejano reported in September on a Travis County boy with a rare gene disorder. An Austin lab is racing to build a drug for him. Read that story here: https://www.eltejanorgv.com/austin-lab-races-to-build-a-drug-for-one-boy-his-mom-needs-3-million/
For now, the FDA has made a plan, not a new rule. The news release gives no timeline.